newsfilter
← Earnings
Earnings Releases·

Vertex Pharmaceuticals — Third Quarter 2026 Earnings Summary

Vertex Pharmaceuticals reported third-quarter 2026 total revenue of $3.44 billion, representing a 12% increase compared to the same period in 2025. The company raised its full-year 2026 revenue guidance to a range of $13.15 billion to $13.25 billion, driven by strong performance in cystic fibrosis therapies and contributions from new products including CASGEVY, JOURNAVX, and PALSONIFY. Vertex completed its acquisition of Crinetics Pharmaceuticals for approximately $9.0 billion net of cash, establishing a fourth commercial pillar in rare endocrine diseases while preparing to launch a fifth franchise in renal medicine with the upcoming PDUFA date for povetacicept.

Company
VERTEX PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology